Alps Advisors Inc. grew its holdings in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 9.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,731 shares of the company’s stock after purchasing an additional 3,546 shares during the period. Alps Advisors Inc. owned about 0.10% of Pacira Pharmaceuticals worth $1,492,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of PCRX. Oppenheimer Asset Management Inc. acquired a new stake in shares of Pacira Pharmaceuticals in the second quarter valued at approximately $114,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Pacira Pharmaceuticals by 12.2% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after purchasing an additional 303 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Pacira Pharmaceuticals by 121.5% in the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after purchasing an additional 1,752 shares during the last quarter. QS Investors LLC acquired a new stake in shares of Pacira Pharmaceuticals in the second quarter valued at approximately $157,000. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares during the last quarter. Institutional investors own 99.64% of the company’s stock.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) traded up $1.90 during mid-day trading on Monday, reaching $42.05. 787,300 shares of the company’s stock were exchanged, compared to its average volume of 840,020. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. Pacira Pharmaceuticals, Inc. has a 1 year low of $29.81 and a 1 year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same period in the previous year, the business posted $0.20 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. sell-side analysts anticipate that Pacira Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Alps Advisors Inc. Acquires 3,546 Shares of Pacira Pharmaceuticals, Inc. (PCRX)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/13/alps-advisors-inc-acquires-3546-shares-of-pacira-pharmaceuticals-inc-pcrx.html.

A number of analysts have recently issued reports on the stock. BMO Capital Markets lowered their price objective on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating on the stock in a report on Thursday, August 3rd. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday. Canaccord Genuity reiterated a “buy” rating and issued a $56.00 price objective on shares of Pacira Pharmaceuticals in a report on Monday, July 31st. ValuEngine downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, HC Wainwright set a $59.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $49.71.

In other news, Director Paul J. Hastings sold 1,044 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total value of $37,740.60. Following the completion of the sale, the director now owns 3,518 shares of the company’s stock, valued at $127,175.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the completion of the sale, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at approximately $783,216. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,390 shares of company stock valued at $1,215,480. Company insiders own 6.60% of the company’s stock.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.